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Background: The Middle East Respiratory Syndrome (MERS) is a viral respiratory disease caused by a member of 
the coronaviruses called Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The co-infections of MERS-
CoV with other respiratory viruses have been documented in rare cases in the scientific literature. This study was 
carried out to determine whether confection of MERS-CoV occurs with other respiratory viruses in Saudi Arabia. 
Methods: Nasopharyngeal swabs samples of 57 MERS-CoV positive outpatients were collected using flocked swabs. 
Nucleic acid was extracted from each sample using commercial NucliSens easyMAG system. Amplification was 
performed by multiplex RT-PCR using Fast Track Diagnostics Respiratory Pathogen 33. Data were analyzed with 
SPSS software version 19 and comparison of variables was done with Fisher Exact test, with p value <0.05 
considered significant. 
Results: Six of the total 57 MERS-COV patients (35 males, 22 females) were positive for co-infection of MERS CoV 
with other respiratory viruses, giving a prevalence rate of 10.5%, with 14.5% (5/35) in males and 4.5% (1/22) in 
females (OR=3.500, 95% CI=0.3806-32.188, p=0.3889). The prevalence of co-infections was significantly higher 
among non-Saudis (23.8%, 5/21) than Saudis (2.8%, 1/36) (OR=0.09143, 95% CI=0.009855-0.8485, p=0.0217), 
and among the age group 18-34 years (25%, 3/12) than other age groups (X2=3.649, p=0.1613). Human rhinovirus 
(HRV) was found in 2 of the 6 (33.3%) patients with co-infection while the other viruses were found in each of the 
remaining 4 patients.  
Conclusion: Our study confirms that MERS-CoV co-infects with other respiratory viruses in Saudi Arabia. 
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Abstrait: 
 
Contexte: Le syndrome respiratoire du Moyen-Orient (MERS) est une maladie respiratoire virale causée par un 
membre des coronavirus appelé coronavirus du syndrome respiratoire du Moyen-Orient (MERS-CoV). Les co-
infections de MERS-CoV avec d'autres virus respiratoires ont été documentées dans de rares cas dans la littérature 
scientifique. Cette étude a été réalisée pour déterminer si la confection du MERS-CoV se produit avec d'autres virus 
respiratoires en Arabie saoudite.                                          








l'aide d'écouvillons floqués. L'acide nucléique a été extrait de chaque échantillon en utilisant le système NucliSens 
easyMAG commercial. L'amplification a été réalisée par RT-PCR multiplex en utilisant Fast Track Diagnostics 
Respiratory Pathogen 33. Les données ont été analysées avec le logiciel SPSS version 19 et la comparaison des 
variables a été effectuée avec le test Fisher Exact, avec une valeur p<0,05 considérée comme significative. 
Résultats: Six des 57 patients MERS-COV (35 hommes, 22 femmes) étaient positifs pour la co-infection de MERS 
CoV avec d'autres virus respiratoires, donnant un taux de prévalence de 10,5%, avec 14,5% (5/35) chez les hommes 
et 4,5% (1/22) chez les femelles (OR 3.500, 95% CI 0.3806-32.188, p=0.3889). La prévalence des co-infections 
était plus élevée chez les non-saoudiens (23.8%, 5/21) que chez les saoudiens (2.8%, 1/36) (OR=0.09143, 95% 
CI=0.009855-0.8485, p=0.0217) et parmi le groupe d'âge de 18 à 34 ans (25%, 3/12) que dans les autres groupes 
d'âge (X2=3.649, p=0.1613). Le rhinovirus humain (VRC) a été trouvé chez 2 des 6 (33,3%) patients co-infectés 
tandis que les autres virus ont été trouvés chez chacun des 4 patients restants. 
Conclusion: Notre étude confirme que le MERS-CoV co-infecte avec d'autres virus respiratoires en Arabie Saoudite. 
 




 The Middle East Respiratory Syndrome 
is a viral respiratory disease caused by member 
of a coronavirus called Middle East Respiratory 
Syndrome Coronavirus (MERS-CoV). The virus 
was first discovered in Saudi Arabia in Sept- 
ember 2012. The health officials carried out a 
retrospective investigation later and identified 
that the first known cases of MERS occurred in 
Jordan in April 2012 (1). After its first identi- 
fication in Saudi Arabia, MERS rapidly spread to 
other countries, resulting in health crises at the 
international level. As of June 2015, MERS-CoV 
had spread to more than 20 countries (2,3). The 
morbidity and mortality caused by MERS-CoV 
were particularly alarming, with mortality rate 
approaching 60% (4). By June 19, 2015, a total 
of 1035 confirmed cases of MERS-CoV were rep- 
orted by the Ministry of Health in Saudi Arabia 
with 458 deaths (case fatality rate of 44%).  
 The clinical spectrum of MERS-CoV dis- 
ease ranges from asymptomatic or mild respi- 
ratory symptoms to severe acute respiratory 
disease and ultimately death. The typical sym- 
ptoms of MERS include cough, shortness of 
breath and fever (5). Pneumonia is a common 
finding but is not always present. Others such as 
gastrointestinal symptoms like diarrhea have 
also been reported. About three to four out of 
every ten patients or rather 36% of patients 
reported with MERS have succumbed to the 
illness (6). In its severe form, MERS can cause 
respiratory failure that will warrant mechanical 
ventilation support in an intensive care unit. 
Severe disease occurs in older populations, 
immunosuppressed, and those with underlying 
chronic diseases such as diabetes, chronic lung 
disease and cancer (2). 
 The MERS-CoV virus is a zoonotic type 
transmitted from animals to humans. The 
studies on the origins of the virus are still 
inconclusive, but according to an analysis of the 
different genomes of the virus, it is believed that 
the virus originated in bats and was later 
transmitted to camels in the distant past (7). 
The zoonotic transmission is still not fully 
understood, however, studies on the disease 
point towards camels as the major reservoir 
host for the virus and thus the source of 
infection in humans. Various strains of the virus, 
which are identical to the human strains, have 
been isolated from camels in most countries, 
such as Oman, Qatar, Egypt, and Saudi Arabia. 
 There is yet no vaccine or specific treat- 
ment available at the moment for the disease. 
Treatment is basically supportive and entirely 
dependent on the patient’s clinical condition at 
the time of presentation. Standard precautions 
should be observed by people visiting farms, 
barns or other places where contact with camels 
is highly probable. These precautions include 
regular hand washing before and after touching 
animals and importantly, avoiding contacts with 
sick animals (8). Consumption of raw or under- 
cooked meat and milk is a risk factor for zoonotic 
transmission, therefore, animal products should 
be processed appropriately through cooking or 
pasteurization and handled with care to avoid 
cross-contamination with uncooked food items. 
Although, camel products have proven to be 
nutritious, they should only be consumed after 
cooking or heat treatment or pasteurization (9). 
Persons who are immunocompromised or have 
renal failure, diabetes and chronic lung disease 
are considered to be at high-risk for severe 
MERS-CoV infection. These groups of individuals 
should hence avoid contact with camels or 
consumption of raw camel products (2). 
 Co-infections of MERS-CoV with other 
respiratory viruses have been documented in 
rare cases in the scientific literature (11,12), 
however, co-infection of other respiratory 
viruses within themselves is common and has 
been well documented (13). Also, some studies 
have reported that co-infection of different 
variants of MERS-CoV does occur (14), but there 
is very little data available to date to confirm co-
infections of MERS-CoV with other respiratory 
viruses. This study was therefore conducted to 








virus occurs with other respiratory viruses, the 
objective of which is to determine the preva- 
lence rate of co-infections of MERS-CoV with 
other respiratory viruses in Saudi Arabia. 
 
Materials and method: 
 
Study setting and design 
 The study was a descriptive cross-
sectional design conducted in Microbiology Dep- 
artment, King Abdulaziz University, Jeddah, 
Saudi Arabia, from the period of December 2015 
to May 2016.  
 
Subjects and sample collection 
 A total of 57 subjects (35 males and 22 
females) of all age groups positive for MERS 
COV infection in the outpatient department of 
five regional laboratories (that perform diag- 
nostic tests only), distributed in different regions 
of the Kingdom of Saudi Arabia, were enrolled 
for the study. Ethical approval was obtained 
from the Scientific Research Ethics Committee 
of the King Abdulaziz University, Saudi Arabia. 
Informed consent of each adult subject and 
assent of children were also obtained. 
 Nasopharyngeal swab was collected 
from each subject with flocked swab, which was 
inserted into the nostril towards the pharynx 
until resistance was felt. Swab was then rotated 
three times to obtain samples containing epith- 
elial cells. All swabs were put in virus transport 
media (VTM) and transported at -80oC to the 
main Scientific Research Laboratory of King 




 All the clinical and laboratory data of 
subjects were collected via the Health Electronic 
Surveillance Network (HESN), the national surv- 
eillance network for reporting infectious dis- 
eases and outbreaks in Saudi Arabia. 
 
Nucleic acid extraction 
 Nucleic acid was extracted from 200 µl 
of the nasopharyngeal sample using NucliSens 
easyMAG system (BioMérieux, USA) following 
the manufacturer’s instructions. The extracted 
nucleic acid was either amplified immediately or 
stored at -80oC until needed.  
 
Multiplex RT-PCR with Fast Track Diagnostics 
Respiratory Pathogen 33 
 The extracted nucleic acid was amplified 
by a one-step multiplex real time PCR using the 
FTD Respiratory Pathogens (FTD-RP33) assay 
version 3 which consists of eight-tube multiplex 
for the detection of respiratory pathogens genes 
(viruses and bacteria) by TaqMan® technology.  
 Tube 1 multiplex assay was for influenza 
A (FluA), influenza B (FluB), influenza A (H1N1) 
swine lineage, and rhinovirus; tube 2 assay was 
for coronavirus NL63, coronavirus 229E, corona- 
virus OC43, and coronavirus HKU1; tube 3 assay 
was for parainfluenza 2, parainfluenza 3, para- 
influenza 4, and internal control; tube 4 assay 
was for parainfluenza 1, human metapneumo- 
virus A/B, bocavirus, and Mycoplasma pneu- 
moniae; tube 5 assay was for respiratory syn- 
cytial viruses A/B, adenovirus, enterovirus, and 
parechovirus; tube 6 assay was for Chlamydia 
pneumoniae, Streptococcus pneumoniae, Hae- 
mophilus influenzae type B, and Staphylococcus 
aureus; tube 7 assay was for Klebsiella pneu- 
moniae, Legionella pneumophila/Legionella lon-
gbeachae, Salmonella spp, and Pneumocystis 
jirovecii; while tube 8 assay was for Moraxella 
catarrhalis, Bordetella spp (except Bordetella 
parapertussis), Haemophilus influenzae, and 
influenza C (FluC).  
 Five microliters of the template were 
used for each of the eight multiplex PCR assays. 
An internal control (BMV), which was included in 
the FTD kit, was run along each patient sample 
in the PCR assay. The thermocycling conditions 
were as follows; 95oC for 10 min and 50oC for 
15 min, followed by 40 cycles of 95oC for 8 s and 
60oC for 34 s. 
 
Statistical analysis 
 Data were analyzed using SPSS soft- 
ware version 19 (SPSS, Chicago, IL, USA) and 
the openly available statistical software environ- 
ment R version 2.10.1. Comparison of data was 
done using Fisher Exact test, and p value < 0.05 





 Of the 57 patients tested (35 males, 22 
females), 6 were confirmed positive for one or 
more respiratory viruses, given a co-infection 
prevalence rate of 10.5%. The prevalence rate 
of 14.5% (5/35) in the males was higher 
(though not significantly) than the rate of 4.5% 
(1/22) in the females (OR=3.500, 95%CI= 
0.3806-32.188, p=0.3889). The co-infection 
rate of 23.8% (5/21) among non-Saudis was 
significantly higher than 2.8% rate (1/36) 
among Saudis (OR=0.09143, 95%CI=0.009855 
-0.8485, p=0.0217). Co-infection of MERS-CoV 
with other respiratory viruses progressively 
decreased with age, with prevalence higher in 
patients below 50 years (14.7%, 5/34) than 
patients above 50 years (4.3%, 1/23) (OR=3.79 
95% CI=0.4928-34.853, p=0.3846), with rate 
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No of patients with 
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Age group (years) 
 18 - 34 
 35 – 49 

























Age group (years) 
 < 50 













































X2=Chi square; OR=Odds Ratio; CI=Confidence Interval; MERS-CoV=Middle East Respiratory Syndrome-Coronavirus; *=statistically significant 
 
 
Table 2: Respiratory viruses identified in patients positive for MERS-COV 
 
 
Cor43 =Coronavirus OC43; Cor229 = Coronavirus 229E; FluA = Influenza A; H1N1 = Influenza A swine lineage; RSV = Respiratory Syncytial 
Virus A/B; HMPV = Human Metapneumovirus A/B; HRV = Human rhinovirus; HBoV = Human bocavirus. 
 
Table 3: Demographic statistics of patients co-infected with other viruses indicating each virus 
 
Cor43 =Coronavirus OC43; Cor229 = Coronavirus 229E; FluA = Influenza A; H1N1 = Influenza A swine lineage; RSV = Respiratory Syncytial Virus 
A/B; HMPV = Human Metapneumovirus A/B; HRV = Human rhinovirus; HBoV = Human bocavirus. 
 
 
followed by those patients aged between 35-49 
years (9.1%, 2/22) and patients above 50 years 
(4.3%, 1/23) (X2=3.649, p=0.1613) (Table 1). 
Two of the six patients with co-infection were 
admitted on suspicion of MERS CoV, based on 
symptoms while and two were due to contact 
with the camel. Of those admitted, two died, 
another one was isolated while the two patients 
admitted due to contact with camel recovered 
and were discharged. Of the 6 patients, 4 are 
from Riyadh city, and 1 each from Jeddah and 
Kharj.  
Patient code Virus detected 
3015201185 HBoV 
3015201197 Cor43 




Viruses Number of 
patients 
Age group (years) (number and %) Gender (number and %) 
Total number  18-34 35-49 over 50 Male Female 
RSV 1 0 0 1 (100) 0 1 (100) 
HRV 2 1 (50) 1 (50) 0 1 (100) 0 
HBoV 1 1 (100) 0 0 1 (100) 0 
HMPV 1 1 (100) 0 0 1 0 
Cor229 1 1 (100) 0 0 1 (100) 0 
Cor43 1 0 1 (100) 0 1 (100) 0 
FluA 1 1 (100) 0 0 1 (100) 0 








Viral prevalence and clinical profiles of patients 
 RT-PCR was utilized in the initial test for 
MERS-CoV in the entire sample collected. 
Consistent with the existing circulation pattern 
and prevalence of MER-CoV in Saudi, 6 samples 
tested positive for co-infection with other respi- 
ratory viruses indicating few nasal carriages of 
viruses. As illustrated in Table 2, 5 patients were 
co-infected with a single respiratory virus while 
1 patient was co-infected with four respiratory 
viruses. Human rhinovirus (HRV) was the most 
prevalent, infecting two of the six patients, while 
the other viruses infected single patient. In the 
patient with MERS-CoV, there was co-infection 
with HRV, Cor229, FluA, and H1N1 (Table 2). 
The only virus found in a female patient was RSV 
while the rest were found in the males. The co-
infection was more frequent in age group 18-34 




 In the current study of 57 MERS-CoV 
positive outpatients in these regional labora- 
tories in Saudi Arabia, co-infection prevalence 
rate of MERS-CoV with other respiratory viru- 
ses was 10.5%. This finding is consistent with 
those of previous studies indicating that co-
infection of MERS-CoV with other respiratory 
viruses has been documented to be low (11, 
12). Also, some studies have reported that co-
infection of different variants of MERS-CoV do 
occur (14), however no virus co-infection was 
detected in individuals below 24 years, showing 
that prevalence of co-infection of MER-CoV with 
other viruses is rare in children.  
 In this study, the frequency of co-
infection was higher (though not statistically 
significant) in the males (14.5%) than the 
females (4.5%). The higher prevalence in the 
male could be explained by the lifestyle risk 
factors such as smoking which could expose 
them to upper respiratory tract infections. Co-
infection was significantly higher (p=0.0217) 
among the non-Saudis (23.8%) than the 
Saudis (2.8%), and our data showed that most 
of the co-infections were among immigrants 
from Yemen. Most of the cases (4/6, 66.7%) of 
co-infections were observed in patients from 
Riyadh city while one co-infected patient each 
was from Jeddah and Kharj. This occurrence of 
MERS-CoV co-infection in Riyadh is higher than 
a previous study conducted in Riyadh (13), 
which is not unexpected because, in the earlier 
Riyadh study, the researchers focused on 
children less than five years who were 
inpatient. In contrast, our study focused on 
outpatients in healthcare centers and of all age 
groups.     
 MERS-CoV co-infection occurred more 
frequently in patients below 50 years (14.7%) 
which is consistent with reduced detection of 
co-infection with increasing age. The MERS-
CoV co-infection rate was 25% in patients aged 
18-34 years, followed by those aged 35-49 
years (9.1%), indicating that increased co-
infection of MER-CoV with other viruses was 
higher among middle-aged people in comp- 
arison to children and elderly. It is noteworthy 
that 33% of the co-infected patients died, 
which indicates that co-infection with other 
viruses is a risk factor for death. This high 
mortality agrees with the previous report by the 
Saudi Ministry of Health in 2015 of 458 deaths 
from a total of 1035 confirmed cases of MERS-
CoV with a case fatality rate of 44%.  
 About 83% of the co-infected patients 
were infected with a single respiratory virus 
while 1 patient (16.7%) was co-infected with 
four respiratory viruses. Of all the viruses, HRV 
was most frequent co-infector (25%) affecting 
2 of the 6 patients, while all the other viruses 
had equal frequency of co-infection. One patient 
was co-infected by four viruses (HRV, Cor22S, 
FluA and H1N1). The data show the tendency of 
HRV to co-infect with MER-CoV but also with 
other viruses. This observation is not easily 
explained hence there is need for more research 
on co-infection of HRV with other respiratory 
viruses. The only virus found in a female patient 
was RSV but our data indicates that HRV is the 
most common virus that that co-infect with 
MER-CoV. The prevalence of co-infection in this 
study supports previous research of co-infection 
of MER-CoV with other respiratory viruses.  
 A major concern of virus co-infection is 
the tendency for genetic exchange between 
different viruses through the process of genetic 
recombination that may result in emergence of 
more virulent strains of viruses that have 
increased pathogenicity and enhanced capacity 
for transmission (15). However, our study was 
limited by the rather too few numbers of co-
infection which is inadequate to support any 
hypothesis. Nevertheless, our use of advanced 
molecular diagnostic technique such as the 
multiplex array aided characterization of the co-
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